Global Alzheimer’s Therapeutics Market to 2022 Size,Share,Growth, Trends and Forecast,By Credence Research

Buy Now
Global Alzheimer’s Therapeutics Market Is Expected To
Reach USD 14,856.3 Mn By 2022
Report Description:
The latest market report published by Credence Research, Inc. “Global Alzheimer’s
Therapeutics Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis,
and Forecast, 2016 - 2022,” the Alzheimer’s therapeutics market was valued at USD 8,524.9 Mn
in 2015, and is expected to reach USD 14,856.3 Mn by 2022, expanding at a CAGR of 8.02%
from 2016 to 2022.
Browse the full report Alzheimer’s Therapeutics Market - Growth, Share,
Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at
http://www.credenceresearch.com/report/alzeimers-therapeutic-market
Market Insights
Alzheimer’s disease is a progressive and currently incurable disease, and potential or supportive
treatments have only emerged in the last decade. However, the currently available treatments
are lacking in terms of efficacy or target-specificity. There are two types of drug classes used in
treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-Daspartate
(NMDA) receptor antagonist. ACE inhibitors constitute of galantamine hydrochloride,
donepezil hydrochloride and rivastigmine; NMDA receptor antagonist includes mematidine
hydrochloride. Since the discovery of what plaques and tangles comprised in Alzheimer’s –
amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein respectively. An immense
research and development has been carried out to develop therapeutics which can limit the
rate of synthesis, reduce the toxicity or clear these factors from the brain. However, these
attempts have been largely unsuccessful. Hence, considering the continuously rising Alzheimer
prevalent population, as well as limited drugs available for treatment, Alzheimer’s disease
presents a lucrative opportunity for an effective disease-modifying therapy to enter the market.
Browse All Reports Of This Category:
http://www.credenceresearch.com/industry/pharmaceuticals-market
Pipeline Analysis
The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals),
Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation,
Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The overall
pipeline for Alzeihmer’s is still very much dominated by small molecule drugs. However, there is
still a considerable number of biologics in the pipeline with total 86 molecules, represented
across all stages of development. According to market experts, the diversity of the several
http://www.credenceresearch.com/report/alzeimers-therapeutic-market

Buy Now
molecule types in the biologic group shows a certain level of innovation, with newer avenues
being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted
very few molecules that could potentially replace current treatments during the forecast
period.
Key Market Movements:
Market experts suggest that a family history of Alzheimer’s increases the risk of disease
development by 7.5 times
The incidence and prevalence of Alzheimer’s disease doubles every five years after age 65
years
Currently population of developed countries is at high risk of Alzheimer due to increasing
geriatric population
In developing countries from Asia Pacific and Latin America the awareness related to agespecific
diseases such as dementia or Alzheimer is increasing
Click Here To Download Detail Report: http://www.pdfdevices.com
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non legislative associations, and not-for-benefits. We offer our
customers some assistance with making enduring enhancements to their execution and
understand their most imperative objectives. Over almost a century, we've manufactured a
firm extraordinarily prepared to this task.
Contact Us:
Media Contact
Name: Chris Smith (Global Sales Manager )
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com
http://www.credenceresearch.com/report/alzeimers-therapeutic-market

http://www.credenceresearch.com/report/alzeimers-therapeutic-market
Buy Now